HTRF VHL-Red Ligand is primarily intended to perform affinity binding curves to VHL protein using HTRF® technology.

VHL, also known as von Hippel-Lindau, is involved in many biological processes and is closely associated with the regulation of angiogenesis, cell growth, or cell survival. VHL is one of the most popular E3 ligases recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a targeted protein. VHL interacts with several proteins to form the functional von Hippel-Lindau ubiquitination complex, in which VHL seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and targets various proteins to proteolysis, such as the hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions.

Identifying new PROTAC VHL ligands can improve selective proteasomal-dependent degradation of proteins of interest involved in the onset of diseases such as cancers.

The HTRF VHL-Red Ligand is primarily intended to perform cooperativity binding studies. It enables calculation of the affinity of the VHL-Red Ligand for VHL protein in the presence of the targeted protein of interest. The determination of the Bmax and the Kd of HTRF VHL-Red Ligand for VHL protein, in absence and presence of the targeted protein, enables the accurate preliminary analysis required for studying cooperative effects assessed with the HTRF Human VHL Binding Kit.